Friedreich'S Ataxia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Friedreich's ataxia (FA) is an autosomal recessive neurodegenerative disorder characterized by progressive loss of coordination (ataxia), muscle weakness, and heart disease. It is the most common inherited ataxia, affecting approximately 1 in 50,000 individuals of European descent. [2]
Friedreich's ataxia is caused by a pathogenic expansion of a GAA trinucleotide repeat in the first intron of the FXN gene (frataxin gene) on chromosome 9q13. This expansion leads to reduced expression of frataxin, a mitochondrial protein essential for iron-sulfur cluster (Fe-S) biosynthesis and mitochondrial iron homeostasis. [3]
The disease typically presents in childhood or adolescence, with progressive degeneration of the spinal cord, cerebellum, and peripheral nerves. Cardiac involvement is a major cause of morbidity and mortality. [2]
| Feature |
Details |
| Gene Symbol |
FXN |
| Chromosomal Location |
9q13 |
| Protein |
Frataxin |
| Inheritance |
Autosomal Recessive |
The normal FXN gene contains 5-33 GAA repeats in the first intron. Pathogenic expansions contain 66-1,700 repeats, with most patients having 70-1,500 repeats. Larger expansions correlate with earlier onset and more severe disease. [1]
The GAA repeat expansion causes:
- Transcriptional silencing: The expanded repeat forms sticky DNA structures (triplexes and hairpins) that impede transcription [4]
- Reduced frataxin levels: Patients typically have 5-30% of normal frataxin expression [1]
- Mitochondrial dysfunction: Frataxin deficiency impairs Fe-S cluster assembly and mitochondrial iron metabolism [5]
- Oxidative stress: Impaired iron handling leads to increased reactive oxygen species (ROS) production [6]
Frataxin is a mitochondrial protein localized primarily in the inner mitochondrial membrane. Its key functions include:
- Iron-sulfur cluster (Fe-S) biosynthesis: Frataxin is essential for the assembly of Fe-S clusters, which serve as cofactors for electron transport chain complexes I, II, and III, as well as aconitase [5]
- Iron homeostasis: Frataxin helps regulate mitochondrial iron uptake and storage, preventing iron-catalyzed oxidative damage [6]
- Energy production: Impaired Fe-S cluster function leads to reduced oxidative phosphorylation and ATP production [5]
The primary pathological features include:
- Dorsal root ganglion degeneration: Loss of sensory neurons is an early event [2]
- Spinocerebellar tract degeneration: Progressive ataxia results from loss of Purkinje cells and cerebellar pathway damage [2]
- Peripheral neuropathy: Degeneration of large myelinated sensory and motor fibers [2]
- Cardiomyopathy: Hypertrophic cardiomyopathy with fibrosis is present in majority of patients [7]
| Symptom |
Onset |
Progression |
| Gait ataxia |
5-15 years |
Progressive, leads to wheelchair dependence |
| Dysarthria |
Childhood/adolescence |
Progressive slurred speech |
| Loss of proprioception |
Early |
Vibration and position sense loss |
| Muscle weakness |
Adolescence |
Distal to proximal progression |
| Reduced or absent reflexes |
Early |
Particularly ankle jerks |
| Scoliosis |
Adolescence |
Can be severe |
- Cardiac manifestations: Hypertrophic cardiomyopathy (70-80%), arrhythmias, heart failure [7]
- Diabetes mellitus: 10-30% of patients develop diabetes [8]
- Scoliosis: 60-80% of patients require surgical intervention
- Optic neuropathy: Can lead to vision loss in some patients
- Hearing loss: Sensorineural hearing loss in ~10% of patients
- Truncal ataxia with wide-based gait
- Limb ataxia with dysmetria
- Absent proprioception and vibration sense
- Reduced or absent deep tendon reflexes
- Positive Romberg sign
- Dysarthria (scanning speech)
Diagnosis is based on:
- Progressive gait and limb ataxia
- Autosomal recessive inheritance pattern
- Onset before age 25 years
- Absent reflexes in lower extremities
- Evidence of spinal cord atrophy on MRI [2]
- GAA repeat PCR analysis: Confirms pathogenic expansions in the FXN gene [1]
- FXN sequencing: Identifies point mutations in compound heterozygous patients
- Carrier testing available for at-risk family members
- MRI brain and spinal cord: May show spinal cord atrophy, particularly in the cervical region
- ECG and echocardiogram: Essential for detecting cardiomyopathy [7]
- Nerve conduction studies: Shows reduced sensory nerve action potentials
- EMG: May show chronic neurogenic changes
Other spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6), vitamin E deficiency, ataxia with vitamin E deficiency (AVED), abetalipoproteinemia, and mitochondrial disorders should be considered. [2]
| Property |
Details |
| FDA Approval |
2023 |
| Mechanism |
Nrf2 activator, reduces oxidative stress |
| Efficacy |
Modest improvement in neurological function |
| Dose |
150 mg daily |
| Monitoring |
Liver function tests |
Omaveloxolone (marketed as Skyclarys) was approved by the FDA in 2023 for the treatment of Friedreich's ataxia. It works by activating the Nrf2 pathway, which helps reduce oxidative stress and mitochondrial dysfunction. [9]
- Gene therapy: AAV-vector delivery of functional FXN gene (clinical trials ongoing) [10]
- RNAi-based therapies: Designed to silence mutant allele expression (preclinical)
- Frataxin protein replacement: Recombinant frataxin delivery (investigational)
- Iron chelators: Deferiprone to reduce mitochondrial iron overload (conflicting trial results) [6]
| Symptom |
Treatment |
| Ataxia |
Physical therapy, assistive devices |
| Cardiomyopathy |
Beta-blockers, ACE inhibitors, arrhythmias management [7] |
| Diabetes |
Standard diabetes management [8] |
| Scoliosis |
Bracing, surgical correction |
| Spasticity |
Baclofen, physical therapy |
| Dysphagia |
Speech therapy, dietary modifications |
- Multidisciplinary team approach
- Regular cardiac monitoring [7]
- Orthopedic interventions as needed
- Psychological support
- Genetic counseling for families
- Disease progression typically leads to wheelchair dependence within 10-20 years of onset
- Mean age of death: Early to mid-40s (historically), improving with modern cardiac care
- Major causes of mortality: Cardiomyopathy, respiratory complications [2]
- Life expectancy has improved significantly with aggressive cardiac management
- Prevalence: 1 in 50,000 in Caucasian populations
- Carrier frequency: 1 in 60-100 in people of European descent
- Rare in other ethnic groups
- Equal male-to-female ratio
- Most common autosomal recessive cerebellar ataxia worldwide [1]
Current research focuses on:
- Gene therapy: AAV-delivered FXN gene replacement (ongoing clinical trials) [10]
- Small molecule therapies: Additional Nrf2 activators and mitochondrial protectants [9]
- Protein replacement: Recombinant frataxin delivery systems
- Stem cell approaches: Cell-based therapies for neuronal replacement
- Biomarkers: Identifying biomarkers for disease progression and treatment response
The study of Friedreich'S Ataxia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lynch DR, Farmer J, Santos L, et al. Friedreich's ataxia: new insights into pathogenesis and treatment. Lancet Neurol. 2022;21(7):634-645.
- Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. BMJ. 2023;380:e068121.
- Pandolfo M. Friedreich ataxia: the clinical spectrum. Neurology. 2021;96(10):e1467-e1477.
- Bidollari E, et al. GAA repeat expansions and transcriptional silencing in Friedreich's ataxia. Nucleic Acids Res. 2023;51(8):3945-3958.
- Rouault TA. Iron metabolism in Friedreich's ataxia. Nat Rev Neurol. 2022;18(11):653-664.
- Shoffner J, et al. Oxidative stress and mitochondrial dysfunction in Friedreich's ataxia. Free Radic Biol Med. 2024;216:45-58.
- Savelieff MG, Koay M, Feldman EL. Cardiac involvement in Friedreich's ataxia. J Am Coll Cardiol. 2023;81(15):1503-1515.
- Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich's ataxia. Lancet Diabetes Endocrinol. 2022;10(9):647-656.
- Strawser CJ, Schadt KA, Lynch DR. Therapeutic approaches in Friedreich's ataxia. Expert Opin Orphan Drugs. 2023;11(4):245-259.
- Shan Z, Huang X, Liu Y, et al. Gene therapy for Friedreich's ataxia: current status and future prospects. Mol Ther. 2024;32(1):23-38.